Clinical Trials Logo

Borderline Ovarian Tumors clinical trials

View clinical trials related to Borderline Ovarian Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT03779399 Completed - Ovarian Cancer Clinical Trials

Treg, Th17 Cells, NKT in Epithelial Ovarian Tumor

Start date: December 1, 2011
Phase:
Study type: Observational

The aim of the study was to estimate the percentage and of Treg, Th17 and NKT in peripheral blood and the tissue of the epithelial ovarian tumor and relationship with blood serum level of HE4, CA125, as well as algorithm ROMA. Material and methods Mononuclear cells (PBMCs) were isolated by density gradient centrifugation obtained from peripheral blood and ovarian tissue of patient suffering ovarian pathology. Patient from control group underwent surgery for unexplanied infertility. The percentage of Treg and Th17 , NKT in peripheral blood and the tissue was assessed using the flow cytometry method according to the manufacturer's instructions. The ROMA index was calculated according to the levels of HE4 and CA-125 in serum.

NCT ID: NCT03690440 Completed - Clinical trials for Borderline Ovarian Tumors

Study Describing the Coverage, Cares and the Fertility of Patients of Less Than 45 Years With a Borderline Ovarian Tumor

OPTIBOT
Start date: June 15, 2018
Phase:
Study type: Observational

Retrospective and prospective multi-center study Indication: Fertility-sparing surgery for patients with borderline ovarian tumor and fertility Objectives: - Description of the characteristics of the patients of less than 45 years having a fertility-sparing surgery for borderline ovarian tumors, the modalities of care and their fertility. - Validation of a nomogram as an information medium to the patients concerned on their chance of alive birth according to their personal characteristics Origin and nature of the specific data: - Extraction from the database " Tumeurs Malignes Rares de l'Ovaire " (TMRO) - Collection of retrospective further informations in the participating centers - Data collection from the patients (questionnaires) The data will be identified by the TMRO number allocated to every participant of the TMRO study . Data traffic : TMRO database extraction for the patients with BOT and corresponding to the inclusion criteria, supplied by Arcagy-Gineco. The database will be managed by the coordination team in an anonymous way by means of the patient identifiers of the TMRO base. Enrichment of the base by the anonymous questionnaires filled by the patients and the complementary data transmissions of the centers on anonymised files.